Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Patient self-report and medical record review results were similar for the calcium and vitamin D supplementation QI.Comparison of documented performance and patient self-report according to clinic settingQuality indicatorSLCHRCPRCEMRPSREMRPSREMRPSREvaluation of quality of life (EU)0/147 (0.0%)27/140 (19.3%)0/56 (0.0%)15/52 (28.9%)0/55 (0.0%)18/55 (32.7%)Assessment of cardiovascular risk factors by rheumatologist (US)91/147** (61.9%)14/56** (25.0%)8/55** (14.5%)Assessment of cardiovascular risk factors by family physician50/139* (36.0%)21/51* (41.2%)31/54* (57.4%)Assessment of cardiovascular risk factors by either rheumatologist or family physician107/144*(74.3%)30/53*(56.6%)32/54*(59.3%)Assessment for drug toxicity (EU)141/147**(95.9%)37/138(26.8%)43/56** (76.8%)23/52(44.2%)44/54** (81.5%)20/54 (37.0%)Ophthalmologic review if on hydroxychloroquine as per guidelines (EU)46/103** (44.7%)69/103 (67.0%)11/34** (32.4%)24/31 (77.4%)27/38** (71.1%)33/38 (86.8%)Ophthalmologic review if on glucocorticoids as per guidelines (EU)34/67** (50.8%)45/67 (67.2%)5/22** (22.7%)18/21 (85.7%)16/23** (69.6%)20/23 (86.9%)Counselling when prescribed new medications (US)118/139** (84.9%)116/144 (80.6%)14/48** (29.2%)44/47 (93.6%)26/44** (59.1%)38/44 (86.4%)Calcium and vitamin D supplementation if received prednisolone >7.5 mg for >3 months (US)93/105 (88.6%)94/104 (90.4%)27/31 (87.1%)29/29 (100%)22/24 (91.7%)22/24 (91.7%)All patients should be vaccinated against influenza and pneumococcus (EU)34/147** (23.1%)27/139 (19.4%)1/55** (1.8%)16/50 (32.0%)2/55** (3.6%)8/54 (14.8%)All patients should be vaccinated against influenza: 92/147(62.6%): 34/52(65.4%): 36/55(65.5%)All patients should be vaccinated against pneumococcus: 27/139(19.4%): 16/50(32.0%): 9/54(16.7%)Rheumatologist recommended vaccination?: 82/136* (60.3%): 28/52* (53.9%): 20/55* (36.4%)Influenza vaccination if on immunosuppressants (US)64/96** (66.7%)61/96 (63.5%)5/46** (10.9%)30/43 (69.8%)2/36** (5.6%)24/36 (66.7%)Pneumococcal vaccination if on immunosuppressants (US)21/96** (21.9%)24/91 (26.4%)1/46** (2.2%)16/41 (39.0%)1/34** (2.9%)8/33 (24.2%)Sun avoidance counselling ever (US)27/147* (18.4%)125/144 (86.8%)5/56* (8.9%)45/52 (86.5%)2/55* (3.6%)47/55 (85.5%)Teratogenic medication risk and contraception counselling in reproductive age women (US)42/64** (65.6%)53/63** (84.1%)4/20** (20.0%)9/17** (52.9%)6/14** (42.9%)5/13** (38.5%)Italics: PSR questions that did not match the quality indicator statement exactly as were used to gain additional information and were not used in the per-patient quality indicator performance calculationNote: The differences in the numbers of eligible patients between EMR and PSR are due to missing values if predating EMR or if unanswered by PSRAbbreviations: EMR Electronic medical record review, EU European, HRC Hospital general rheumatology clinic, PRC Private rheumatology clinic, PSR Patient self-report, SLC subspecialty lupus clinic, US United States*p<0.05, **p<0.01
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cross-sectional study.
Cross-sectional study
Examines a population at a particular point in time.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Association of clinic setting with quality indicator performance in systemic lupus erythematosus: a cross-sectional study
Source: Article title.
Patients were deemed eligible if they were over 18 years old and able to consent, met American College of Rheumatology 1997 (ACR) or Systemic Lupus International Collaborating Clinics 2012 (SLICC) classification criteria for SLE [, ], and had at least 12 months duration of follow-up with access to electronic medical records.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Association of clinic setting with quality indicator performance in systemic lupus erythematosus: a cross-sectional study
Cross-sectional study · Arthritis Research & Therapy · 2022
Original publication title
Association of clinic setting with quality indicator performance in systemic lupus erythematosus: a cross-sectional study
© The Author(s) 2022
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Healthcare quality for systemic lupus erythematosus (SLE) is a modifiable target for improving patient outcomes. We aimed to assess the quality of care processes in different clinic settings, comparing a subspecialty lupus clinic with hospital-based and private general rheumatology clinics.
Source: BackgroundAbstract: What methods does the paper describe?
Patients with SLE (n = 258) were recruited in 2016 from a subspecialty lupus clinic (n = 147), two hospital general rheumatology clinics (n = 56) and two private rheumatology clinics (n = 55). Data were collected from medical records and patient questionnaires. Quality of care was assessed using 31 validated SLE quality indicators (QI) encompassing diagnostic work-up, disease and comorbidity assessments, drug monitoring, preventative care and reproductive health. Per-QI performance was measured as a percentage of patients that met the QI relative to the number of patients eligible.
Per-patient QI performance was calculated as a percentage of QIs met relative to the number of eligible QIs for each patient. Per-QI and per-patient QI performance were compared between the three clinic settings, and multiple regression performed to adjust for sociodemographic, disease and healthcare factors.
Source: MethodsAbstract: Results
Per-QI performance was generally high across all clinic settings for diagnostic work-up, comorbidity assessment, lupus nephritis, drug monitoring, prednisolone taper, osteoporosis and pregnancy care. Median [IQR] per-patient performance on eligible QIs was higher in the subspeciality lupus clinic (66.7% [57.1 to 74.1]) than the hospital general rheumatology (52.7% [47.5 to 58.1]) and private rheumatology (50.0% [42.9 to 60.9]) clinics (p <0.001) and the difference remained significant after multivariable adjustment. The subspecialty lupus clinic recorded higher per-QI performance for documentation of disease activity, disease damage, cardiovascular risk factor and drug toxicity assessments, pre-immunosuppression hepatitis and tuberculosis screening, new medication counselling, vaccinations, sun avoidance education and contraception counselling.
Source: ResultsAbstract: Conclusions
SLE patients managed in a subspecialty lupus clinic recorded higher per-patient QI performance compared to hospital general rheumatology and private rheumatology clinics, in part related to better documentation on certain QIs.
Source: ConclusionsAuthors’ abstract
Background
Healthcare quality for systemic lupus erythematosus (SLE) is a modifiable target for improving patient outcomes. We aimed to assess the quality of care processes in different clinic settings, comparing a subspecialty lupus clinic with hospital-based and private general rheumatology clinics.
Methods
Patients with SLE (n = 258) were recruited in 2016 from a subspecialty lupus clinic (n = 147), two hospital general rheumatology clinics (n = 56) and two private rheumatology clinics (n = 55). Data were collected from medical records and patient questionnaires. Quality of care was assessed using 31 validated SLE quality indicators (QI) encompassing diagnostic work-up, disease and comorbidity assessments, drug monitoring, preventative care and reproductive health. Per-QI performance was measured as a percentage of patients that met the QI relative to the number of patients eligible.
Per-patient QI performance was calculated as a percentage of QIs met relative to the number of eligible QIs for each patient. Per-QI and per-patient QI performance were compared between the three clinic settings, and multiple regression performed to adjust for sociodemographic, disease and healthcare factors.
Results
Per-QI performance was generally high across all clinic settings for diagnostic work-up, comorbidity assessment, lupus nephritis, drug monitoring, prednisolone taper, osteoporosis and pregnancy care. Median [IQR] per-patient performance on eligible QIs was higher in the subspeciality lupus clinic (66.7% [57.1 to 74.1]) than the hospital general rheumatology (52.7% [47.5 to 58.1]) and private rheumatology (50.0% [42.9 to 60.9]) clinics (p <0.001) and the difference remained significant after multivariable adjustment. The subspecialty lupus clinic recorded higher per-QI performance for documentation of disease activity, disease damage, cardiovascular risk factor and drug toxicity assessments, pre-immunosuppression hepatitis and tuberculosis screening, new medication counselling, vaccinations, sun avoidance education and contraception counselling.
Conclusions
SLE patients managed in a subspecialty lupus clinic recorded higher per-patient QI performance compared to hospital general rheumatology and private rheumatology clinics, in part related to better documentation on certain QIs.
Supplementary Information
The online version contains supplementary material available at 10.1186/s13075-022-02823-9.
Publication and source details
Original title: Association of clinic setting with quality indicator performance in systemic lupus erythematosus: a cross-sectional study
Sidha Sreedharan; Ning Li; Geoff Littlejohn; Russell Buchanan; Mandana Nikpour; Eric Morand; Alberta Hoi; Vera Golder
Arthritis Research & Therapy · 2022
© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T08:45:53.206951+00:00
DOI: 10.1186/s13075-022-02823-9 · PMC9214991